Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Triptorelin Pamoate 6-month Formulation in Chinese Patients with Prostate Cancer
NCT05590793Phase 3Completed
- Sponsor
- Ipsen
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of triptorelin pamoate in prostate cancer (PCa), sponsored by Ipsen. Started Nov 2022; status: completed.
02
Drugs
triptorelin pamoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05590793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590793.